Search research articles
Contact Us
Filters
Showing results (81-90 of 119) with videos related to
Page
of 12
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 9, 2016
An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients
Geny Piro, Carmine Carbone, Ivana Cataldo, et al.
Frontiers in Cell and Developmental Biology
|
May 16, 2020
Organoid-Transplant Model Systems to Study the Effects of Obesity on the Pancreatic Carcinogenesis <i>in vivo</i>
Francesca Lupo, Geny Piro, Lorena Torroni, et al.
Cancers
|
December 9, 2023
Timing of Initiation of Palliative Chemotherapy in Asymptomatic Patients with Metastatic Pancreatic Cancer: An International Expert Survey and Case-Vignette Study
Simone Augustinus, Hanneke W M van Laarhoven, Geert A Cirkel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 27, 2015
IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation
Zhuonan Zhuang, Huai-Qiang Ju, Mitzi Aguilar, et al.
Medicina (Kaunas, Lithuania)
|
November 11, 2022
Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study
Alessandro Rizzo, Massimiliano Salati, Giorgio Frega, et al.
British Journal of Cancer
|
March 29, 2017
Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis
Uwe Pelzer, Jean-Frédéric Blanc, Davide Melisi, et al.
Therapeutic Advances in Medical Oncology
|
July 21, 2020
A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial
Valeria Merz, Camilla Zecchetto, Francesca Simionato, et al.
British Journal of Cancer
|
October 16, 2018
Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
Davide Melisi, Rocio Garcia-Carbonero, Teresa Macarulla, et al.
Cancer Chemotherapy and Pharmacology
|
March 20, 2019
TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer
Davide Melisi, Rocio Garcia-Carbonero, Teresa Macarulla, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]
|
April 26, 2021
Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients
Davide Melisi, Alessandro Cavaliere, Stefano Gobbo, et al.
Page
of 12
Search research articles
Search
Showing results (81-90 of 119) with videos related to
Sort By:
Page
of 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 9, 2016
An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients
Geny Piro, Carmine Carbone, Ivana Cataldo, et al.
Frontiers in Cell and Developmental Biology
|
May 16, 2020
Organoid-Transplant Model Systems to Study the Effects of Obesity on the Pancreatic Carcinogenesis <i>in vivo</i>
Francesca Lupo, Geny Piro, Lorena Torroni, et al.
Cancers
|
December 9, 2023
Timing of Initiation of Palliative Chemotherapy in Asymptomatic Patients with Metastatic Pancreatic Cancer: An International Expert Survey and Case-Vignette Study
Simone Augustinus, Hanneke W M van Laarhoven, Geert A Cirkel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 27, 2015
IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation
Zhuonan Zhuang, Huai-Qiang Ju, Mitzi Aguilar, et al.
Medicina (Kaunas, Lithuania)
|
November 11, 2022
Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study
Alessandro Rizzo, Massimiliano Salati, Giorgio Frega, et al.
British Journal of Cancer
|
March 29, 2017
Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis
Uwe Pelzer, Jean-Frédéric Blanc, Davide Melisi, et al.
Therapeutic Advances in Medical Oncology
|
July 21, 2020
A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial
Valeria Merz, Camilla Zecchetto, Francesca Simionato, et al.
British Journal of Cancer
|
October 16, 2018
Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
Davide Melisi, Rocio Garcia-Carbonero, Teresa Macarulla, et al.
Cancer Chemotherapy and Pharmacology
|
March 20, 2019
TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer
Davide Melisi, Rocio Garcia-Carbonero, Teresa Macarulla, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]
|
April 26, 2021
Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients
Davide Melisi, Alessandro Cavaliere, Stefano Gobbo, et al.
Page
of 12